The Manila Times

Heron Therapeutics Announces Preliminary, Unaudited Q4 and Full-Year 2025 Net Revenue; ZYNRELEF® Largest Contributor to Q4 Growth

Heron Therapeutics, Inc. (Nasdaq: HRTX) ('Heron” or the 'Company”), a commercial-stage biotechnology company, today announced ...
American Association of Individual Investors

Why Heron Therapeutics, Inc.’s (HRTX) Stock Is Up 10.63%

As of Friday, January 09, Heron Therapeutics, Inc.’s HRTX share price has surged by 10.63%, which has investors questioning ...

Heron Therapeutics, Inc.: Heron Therapeutics Announces Preliminary, Unaudited Q4 and Full-Year 2025 Net Revenue; ZYNRELEF Largest Contributor to Q4 Growth

Heron Therapeutics, Inc. (Nasdaq: HRTX) ("Heron" or the "Company"), a commercial-stage biotechnology company, today announced preliminary, unaudited fourth ...
AgriNews

To Your Good Health: Pulmonary nodules appear, leading to concern about cancer

Some cancers can spread to the lungs. While the appearance of nodules on a CT scan in a person with no known cancer would be ...
KTVZ

Comparing 12 common rheumatoid arthritis prescriptions

SaveHealth reports on common rheumatoid arthritis medications, highlighting their effectiveness, side effects, and cost ...